| ID Source | ID |
|---|---|
| PubMed CID | 2472137 |
| CHEMBL ID | 1535609 |
| CHEBI ID | 105452 |
| Synonym |
|---|
| smr000375804 |
| MLS000770552 , |
| CHEBI:105452 |
| 2-[[5-(furan-2-yl)-1,3,4-oxadiazol-2-yl]sulfanyl]-1-(1h-pyrrol-2-yl)ethanone |
| HMS2663P11 |
| bdbm95020 |
| 2-[[5-(2-furyl)-1,3,4-oxadiazol-2-yl]thio]-1-(1h-pyrrol-2-yl)ethanone |
| 2-[[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]thio]-1-(1h-pyrrol-2-yl)ethanone |
| cid_2472137 |
| CHEMBL1535609 |
| Q27183187 |
| Z18651090 |
| SR-01000063768-1 |
| sr-01000063768 |
| AKOS033635307 |
| Class | Description |
|---|---|
| aryl sulfide | Any organic sulfide in which the sulfur is attached to at least one aromatic group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 30.1313 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 17.7828 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 9.8868 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
| TDP1 protein | Homo sapiens (human) | Potency | 1.0323 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 25.1189 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 28.1838 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 10.0000 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 35.4813 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 44.6684 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 39.8107 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 15.8489 | 0.5406 | 17.6392 | 96.1227 | AID2528 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 3.1623 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 100.0000 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 7.3078 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 14.1254 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 84.9214 | 0.1337 | 25.4129 | 89.1251 | AID720498 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 2.2387 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 47.7548 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 44.6684 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 14.1254 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 23.5357 | 0.0752 | 15.2253 | 39.8107 | AID485360; AID540279 |
| geminin | Homo sapiens (human) | Potency | 5.8048 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 17.7828 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 100.0000 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| low molecular weight phosphotyrosine protein phosphatase isoform c | Homo sapiens (human) | IC50 (µMol) | 80.0000 | 4.9700 | 11.2567 | 19.6000 | AID652005 |
| Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) | IC50 (µMol) | 38.1000 | 2.8600 | 9.6336 | 17.2000 | AID651700 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| guanyl-nucleotide exchange factor activity | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| protein binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| protein domain specific binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| cAMP binding | Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) |
| acid phosphatase activity | Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) |
| protein tyrosine phosphatase activity | Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) |
| non-membrane spanning protein tyrosine phosphatase activity | Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) |
| protein binding | Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||